Probable case
An acute febrile illness with two or more of the following manifestations:
Headache, retro-orbital pain, myalgia, arthralgia, rash, haemorrhagic manifestations, • leucopenia; plus Supportive serology test results (a reciprocal haemagglutination-inhibition antibody titre ≥1280, a comparable IgG enzyme linked immunosorbent assay (ELISA) titre or a positive IgM antibody test on a late acute or convalescent-phase serum specimen); or Occurrence at the same location and time as other confirmed cases of dengue fever The following criteria must all be present: Fever (or history of acute fever) lasting two to seven days, • occasionally biphasic Haemorrhagic tendencies (positive tourniquet test*; • petechiae; ecchymoses or purpura; bleeding from the mucosa, gastrointestinal tract, injection sites, or other locations; haematemesis or melena); Thrombocytopenia • (≤100 000×10 6 cells/l). † Evidence of plasma leakage caused by increased vascular permeability and manifested by at least one of the following: a rise in the packed cell volume ≥20% above average for age, sex, and population; a drop of ≥20% in the packed cell volume after volume replacement treatment; signs of plasma leakage such as pleural effusion, ascites, and hypoproteinaemia *Performed by inflating a blood pressure cuff on the upper arm to a point midway between the systolic and diastolic pressures for five minutes. A test is considered positive when ≥20 petechiae per 2.5 cm area square are observed. The test may be negative or mildly positive during the phase of profound shock. It usually becomes positive, sometimes strongly positive, if the test is conducted after recovery from shock †This value represents a direct count using a phase-contrast microscope (normal is 200 000-500 000×10 6 /l). For outpatients, an approximate count from a peripheral blood smear is acceptable. In normal people, 4-10 platelets per oil-immersion field (100×; the average of the readings from 10 oil-immersion fields is recommended) indicates an adequate platelet count. An average of ≤3 platelets per oil-immersion field is considered low (that is, <100 000×10 
CliniCal Review what are the clinical features of dengue?
Dengue virus infection may be symptomless, particularly in children, or may present as acute fever that is self limiting in most cases. It is often confused with other viral or bacterial illnesses. Acute infection may progress to severe forms of the disease and eventually death. A seminal cohort study of children in Thailand (1962 Thailand ( -1964 showed that dengue haemorrhagic fever (one form of severe dengue) is characterised by extraordinary third space fluid accumulation from leakage of plasma into the extravascular space, which leads to haemoconcentration, hypoalbuminaemia, and cavitary infarction. 7 This study was essential in the development of classification of the clinical forms of dengue and guidelines for treating the disease. Dengue is classified as dengue fever, dengue haemorrhagic fever, or dengue shock syndrome (boxes 1, 2, and 3), depending on its severity and presenting features.
Dengue fever is an acute febrile illness with two or more of the following manifestations: headache, retroorbital pain, myalgia, arthralgia, rash, leucopenia, and mild haemorrhagic symptoms. Warning signals-such as spontaneous or provoked bleeding, vomiting, intense abdominal pain, painful hepatomegaly, breathing discomfort, lethargy, and cavitary infarction (pleural, pericardial, ascites)-usually precede the severe manifestations of dengue (box 4). These warning signals, which appear between the third and seventh days after the onset of acute dengue fever (usually between the fourth and fifth days) when fever subsides, are clinically important as the patient is at increased risk of developing dengue hemorrhagic fever (box 2). The additional signs of circulatory failure indicate dengue shock syndrome (box 3).
9
Dengue hemorrhagic fever presents in a similar fashion both in children and adults, with slight differences in the frequency of manifestations. Whereas petechiae, melena, headache, retro-orbital pain, myalgia, nausea, and vomiting are more common in adults, epistaxis, oliguria, and hepatomegaly are more frequent in children.
10 which haematological and biochemical abnormalities occur in dengue? Patient with dengue fever usually present with leucopenia, with or without lymphocytosis and lymphocyte atypia. If the clinical condition develops into dengue haemorrhagic fever, a gradual increase in packed cell volume occurs, accompanied by thrombocytopenia (platelet counts <100 000×10 6 /l), increase in prothrombin, partial thromboplastin and thrombin times, and reduction in fibrinogen, factor VIII, factor XII, antithrombin, antiplasmin, and serum albumin. Albuminuria may be observed.
9 11 Hepatic manifestations such as hepatomegaly and increased serum levels of aspartate aminotransferase and alanine aminotransferase are often observed in dengue fever and dengue haemorrhagic fever. Increased serum levels of bilirubin, alkaline phosphatase, and γ-glutamyltransferase are observed in variable frequency. [12] [13] [14] neurological manifestations in dengue Neurological manifestations have been reported in prospective and retrospective clinical studies that used different diagnosis variables; the findings are not standardised. Reported neurological manifestations include altered consciousness, lethargy, somnolence, and, more rarely, agitation and generalised seizures. Focal upper neurone signs, extrapyramidal features, and transverse myelitis have been reported. 15 Normal or moderately raised pressure and lymphocytosis (5-500×10 6 cells/l) in the cerebrospinal fluids can be observed. All of the criteria for dengue haemorrhagic fever (box 2) must be present, plus evidence of circulatory failure manifested by:
Rapid and weak pulse and narrow pulse pressure (<20 mm • Hg (2.7 kPa)) or Hypotension for age, and cold, clammy skin and • restlessness what predisposes a patient to developing dengue haemorrhagic fever? A controversial theory based on epidemiological and biological evidence suggests that the great majority of cases of dengue haemorrhagic fever occur after a secondary infection by a different viral serotype, which produces the phenomenon of antibody dependent enhancement (the infecting virus forms a complex interaction with non-neutralising antibodies, thus enhancing phagocytosis by mononuclear cells). Sequential circulation of the four serotypes, irrespective of the order, establishes a complex interaction of heterotypic antibodies, producing increased viral replication in the host, a phenomenon that is thought to play an important role in triggering the physiopathological mechanisms that determine the severity of the disease. 21 The enhanced virulence of some strains of dengue virus has also been suggested as a risk factor for occurrence of dengue haemorrhagic fever.
22
Case series have suggested that individuals with some comorbidities (diabetes, allergies, or hypertension) are more susceptible to dengue haemorrhagic fever and that black individuals seem to be more resistant to this severe form of dengue.
23 24 A case-control genetic study in Brazil showed an inverse association between African ancestry and occurrence of dengue haemorrhagic fever.
25
How to treat dengue fever? Treatment for dengue fever is supportive as no specific curative treatment exists. Fluid replacement is the only recognised form of intervention for most patients with dengue haemorrhagic fever and dengue shock syndrome. Early diagnosis and optimal clinical management reduces the likelihood of death in both paediatric and adult patients. 10 The therapeutic approach to preventing deaths from dengue haemorrhagic fever must be defined by the dynamic evolution of the disease. Therapeutic regimens proposed in early clinical studies 7 26 informed the World Health Organization's 1997 guidelines. 9 The table presents an adaptation of these guidelines that is based both on the old evidence 7 26 and on newer clinical data that compare different and more aggressive 
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Treatment guidelines according to level of dengue severity Haemoconcentration: raised packed cell volume (>10% above baseline value). In the absence of this information consider the following values for increased haemoconcentrations-children, >42%; women, >44%; men, >50%; with or without other warning signs Intravenous hydration with crystalloid solution and plasma expander in a healthcare unit under medical supervision for at least 24 hours; provide sufficient fluids to prevent shock; antipyretics and analgesics*; clinical re-evaluation and measurement of packed cell volume after hydration Level E Shock (pulse pressure <10 mm Hg)
Ideally in an intensive healthcare unit; intravenous colloid solution (hydroxy ethyl starch 6%, molecular weight 200,000; Dextran 70) is mandatory Haemorrhagic manifestations present or absent Transfusion of fresh whole blood or fresh frozen plasma in case of severe gastrointestinal bleeding Essential laboratory tests: complete blood count, determination of serum albumin, chest radiography. Other tests might be needed: glucose, urea, creatinine, electrolytes, serum aspartate aminotransferase and serum alanine aminotransferase, blood gas analysis, and ultrasonography of abdomen and chest. *Do not use aspirin or anti-inflammatory drugs.
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schedules for fluid resuscitation in the early phase of treatment.
27-29
Treatment schemes are organised in five levels according to dengue severity. When the patient is in severity level A (no warning signs) or B (no warning signs but mild spontaneous bleeding events or a positive tourniquet test) admission to hospital is not usually necessary. Treatment centred on adequate oral hydration and control of fever with antipyretics (preferably paracetamol, as aspirin and anti-inflammatory drugs are contraindicated) can be provided in outpatient clinics. Admission to hospital is required to enable fast and monitored hydration in the event of haemoconcentration (a rise in packed cell volume to a level ≤10% above the patient's own baseline) or thrombocytopenia, with or without warning signs (indicating progression to severity level C). An increase in packed cell volume to a level >10% above the patient's own baseline strongly suggests third space plasma leakage, the main feature of dengue haemorrhagic fever (severity level D). At this stage, restoring circulatory volume by rapid infusion with an intravenous crystalloid and a plasma expander is mandatory.
9 26-30
A patient who seems to be haemodynamically compromised also requires continuous monitoring of vital signs, diuresis, and fluid balance and repeated measurements of packed cell volume and serum albumin and urea. Intensive supportive care could prevent the patient from developing dengue shock syndrome. If the patient reaches severity level E (dengue shock syndrome with pulse pressure <10 mm Hg) transfer to an intensive care unit for rapid intravenous colloids solution is considered the ideal management strategy.
27--30
Severe gastrointestinal haemorrhage is a rare event that requires the administration of fresh blood or fresh frozen plasma.
26
A patient's condition may evolve quickly from a moderate to a severe stage of illness, taking only a few hours to develop shock. Close monitoring of clinical signs and laboratory measurements are therefore the keys for good clinical management. However, inappropriate administration of intravenous fluid, especially in children, could be dangerous and must be prevented.
How might dengue be prevented? International efforts are under way to develop an efficacious vaccine against dengue, and some tetravalent vaccine candidates are in phase 2 or phase 3 trials. 31 To date, the only alternative control strategy is to reduce the vector population, a strategy in general centred on the use of chemicals. However, this approach is expensive, poorly sustainable, and environmentally aggressive, with low or no effectiveness in reducing levels of dengue transmission.
4 32 Other approaches have been tried without success. For example, a recent randomised trial evaluating a community involvement strategy embedded in a traditional control programme found that the intervention was effective in reducing the Aedes aegypti population, but the trial did not investigate the effect of the intervention on the transmission of the 
How to reduce deaths during epidemics and in areas where dengue is endemic?
The observed decrease in the death rates for dengue haemorrhagic fever has occurred as a consequence of the advances in the clinical management of the disease. 34 The training of health professionals and the promotion of information to increase awareness of the warning signs of severe dengue are important; the latter measure would alert populations living in areas where dengue is endemic and where epidemics exist to seek medical care in the early stages of a potential severe disease.
Epidemics are a huge challenge for healthcare services to provide high quality care. For example, at the peak of the 2008 dengue epidemic over 1000 cases of dengue fever or dengue haemorrhagic fever were recorded in a single day in Rio de Janeiro, B razil, creating fear, despair, and chaos in the health system. 4 35 No standard strategy exists for managing an epidemic, especially those epidemics with a great proportion of dengue hemorrhagic fever. But experience has shown that additional resources and procedures are needed to enable people with fever to access health care easily, otherwise the care of routine patients will be affected. The idea is that the patient with fever would be guaranteed immediate care at healthcare units. But it is also important that healthcare professionals follow simple and reliable protocols for diagnosis and treatment based on the best current scientific knowledge, and patients must be sufficiently informed to be highly alert to the warning signs of dengue. In serious epidemics, all available staff need to be mobilised.
